サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1656921

in situハイブリダイゼーションの世界市場：洞察、競合情勢、市場予測：2032年

In Situ Hybridization - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
in situハイブリダイゼーションの世界市場：洞察、競合情勢、市場予測：2032年
出版日: 2025年01月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

in situハイブリダイゼーションの市場規模は、2024年には16億7,355万米ドルとなりました。同市場は、2025年から2032年までの予測期間中に7.12％のCAGRで拡大し、2032年には28億8,613万米ドルに達すると予測されています。in-situハイブリダイゼーションの需要は、主にがんと遺伝性疾患の有病率の上昇によって顕著に急増しています。加えて、神経疾患や感染症の動向もこの需要をさらに後押ししています。これと相まって、研究開発活動の活発化と資金調達がin situハイブリダイゼーション市場の成長軌道を後押しする重要な要因となっています。この成長動向は、2025年から2032年までの予測期間を通じて持続し、繁栄すると予想されます。

ISHは、ダウン症やエドワード症候群などの先天性疾患の診断に用いられます。調査によって、特定の遺伝子が組織や臓器でどのように発現しているかを分析し、発生プロセスや疾患、生理機能への関与に光を当てることができます。そのため、遺伝性疾患や何らかの希少疾患の罹患者数の増加は、市場の成長に寄与すると予想されます。例えば、世界経済フォーラムが2023年2月に発表した報告書によると、2019年には約4億7,500万人が希少疾患に罹患しており、これは世界人口の10％を占めています。今後5年以内に、約1,520万人が希少疾患の特定に特化した臨床ゲノム検査を受けると予想されています。

Johnson & Johnsonが2023年2月に発表した記事によると、2023年現在、世界全体で3億人以上が希少疾患に罹患していると推定されています。蛍光in situハイブリダイゼーション（FISH）は、染色体異常に起因する疾患の診断を助けるために病理医が使用する遺伝子検査技術です。したがって、遺伝性疾患や希少疾患の増加は、in situハイブリダイゼーションの広範な使用に寄与しており、これが市場成長を促進すると予想されます。

世界保健機関（WHO）が2022年に発表したデータによると、2020年には世界中で乳がん約226万例、肺がん221万例、結腸・直腸がん193万例、前立腺がん141万例、胃がん109万例が報告されています。

2021年にGlobal Cancer Observatoryが発表したデータによると、2020年には世界中で約54万4,352例の非ホジキンリンパ腫と8万3,087例のホジキンリンパ腫が報告されました。同じ情報源によると、2020年には世界中で約474,519例の白血病と約176,404例の多発性骨髄腫が報告されています。In situハイブリダイゼーションは、がんに関連する遺伝子発現の変化や染色体異常を調べる貴重なツールとして機能し、潜在的な診断指標や治療介入の標的の発見に役立ち、市場の成長を促進しています。

HIVや肝炎などの感染症が増加していることも、in situハイブリダイゼーション（ISH）市場の主要な促進要因です。in situハイブリダイゼーション（ISH）は、感染性病原体を検出するために、実験室医学と分子遺伝学技術を融合させたものです。蛍光in situハイブリダイゼーション（FISH）は特に、細胞構造の完全性を維持しながら、多様なサンプル内のヌクレオチド配列を同定し、ピンポイントで特定するのに役立ちます。世界保健機関（WHO）の2022年の発表によると、2022年には全世界で約3億5,400万人がB型またはC型肝炎に感染していると推定されています。

政府の支援と資金は、希少疾病パートナーシップから得られる価値を最大化することに向けられており、その包括的な目標は、希少疾病分野における研究と技術革新のレベルを向上させることです。例えば、2023年9月、英国の研究・イノベーション部門は、総額約7億9,850万米ドル（6億2,700万英ポンド）の投資を行い、希少疾患研究の推進を目的とした様々なイニシアチブを包含しています。特に、2016年から2021年の間に1億2,690万米ドル（9,970万英ポンド）がMRCフェローシップとNIHRキャリア開発賞に割り当てられており、希少疾患研究の取り組みを取り巻く包括的な支援ネットワークが示されています。

当レポートでは、世界のin situハイブリダイゼーション市場について調査し、市場の概要とともに、製品タイプ別、技術別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 in situハイブリダイゼーション市場レポートのイントロダクション

第2章 in situハイブリダイゼーション市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第5章 in situハイブリダイゼーション市場の主な要因分析

  • in situハイブリダイゼーション市場の促進要因
  • in situハイブリダイゼーション市場の抑制要因と課題
  • in situハイブリダイゼーション市場の機会

第6章 in situハイブリダイゼーション市場におけるポーターのファイブフォース分析

第7章 in situハイブリダイゼーション市場評価

  • 製品タイプ別
    • 機器
    • 試薬とキット
    • ソフトウェア
  • 技術別
    • 蛍光in situハイブリダイゼーション（FISH）
    • クロモジェニックin situハイブリダイゼーション（CISH）
    • その他
  • 用途別
    • がん診断
    • 遺伝性疾患
    • 感染症
  • エンドユーザー別
    • 病院・診療所
    • 診断センター
    • 製薬会社・バイオテクノロジー企業
    • 学術機関・政府機関
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 in situハイブリダイゼーション市場の企業と製品プロファイル

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • PerkinElmer Inc.
  • Sysmex Corporation
  • Biocare Medical, LLC
  • Genemed Biotechnologies, Inc.
  • NeoGenomics Laboratories
  • Advanced Cell Diagnostics, Inc.
  • BioView
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • QIAGEN
  • BioGenex
  • ZYTOVISION GmbH
  • Promega Corporation
  • Illumina, Inc.
  • Danaher Corporation

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: In Situ Hybridization Market in Global (2022-2032)
  • Table 3: In Situ Hybridization Market in Global by Product Type (2022-2032)
  • Table 4: In Situ Hybridization Market in Global by Technology (2022-2032)
  • Table 5: In Situ Hybridization Market in Global by Application (2022-2032)
  • Table 6: In Situ Hybridization Market in Global by End-User (2022-2032)
  • Table 7: In Situ Hybridization Market in Global by Geography (2022-2032)
  • Table 8: In Situ Hybridization Market in North America (2022-2032)
  • Table 9: In Situ Hybridization Market in the US (2022-2032)
  • Table 10: In Situ Hybridization Market in Canada (2022-2032)
  • Table 11: In Situ Hybridization Market in Mexico (2022-2032)
  • Table 12: In Situ Hybridization Market in Europe (2022-2032)
  • Table 13: In Situ Hybridization Market in France (2022-2032)
  • Table 14: In Situ Hybridization Market in Germany (2022-2032)
  • Table 15: In Situ Hybridization Market in the United Kingdom (2022-2032)
  • Table 16: In Situ Hybridization Market in Italy (2022-2032)
  • Table 17: In Situ Hybridization Market in Spain (2022-2032)
  • Table 18: In Situ Hybridization Market in Rest of Europe (2022-2032)
  • Table 19: In Situ Hybridization Market in Asia-Pacific (2022-2032)
  • Table 20: In Situ Hybridization Market in China (2022-2032)
  • Table 21: In Situ Hybridization Market in Japan (2022-2032)
  • Table 22: In Situ Hybridization Market in India (2022-2032)
  • Table 23: In Situ Hybridization Market in Australia (2022-2032)
  • Table 24: In Situ Hybridization Market in South Korea (2022-2032)
  • Table 25: In Situ Hybridization Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: In Situ Hybridization Market in Rest of the World (2022-2032)
  • Table 27: In Situ Hybridization Market in the Middle East (2022-2032)
  • Table 28: In Situ Hybridization Market in Africa (2022-2032)
  • Table 29: In Situ Hybridization Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: In Situ Hybridization Market in Global (2022-2032)
  • Figure 3: In Situ Hybridization Market in Global by Product Type (2022-2032)
  • Figure 4: In Situ Hybridization Market in Global by Technology (2022-2032)
  • Figure 5: In Situ Hybridization Market in Global by Application (2022-2032)
  • Figure 6: In Situ Hybridization Market in Global by End-User (2022-2032)
  • Figure 7: In Situ Hybridization Market in Global by Geography (2022-2032)
  • Figure 8: In Situ Hybridization Market in North America (2022-2032)
  • Figure 9: In Situ Hybridization Market in the US (2022-2032)
  • Figure 10: In Situ Hybridization Market in Canada (2022-2032)
  • Figure 11: In Situ Hybridization Market in Mexico (2022-2032)
  • Figure 12: In Situ Hybridization Market in Europe (2022-2032)
  • Figure 13: In Situ Hybridization Market in France (2022-2032)
  • Figure 14: In Situ Hybridization Market in Germany (2022-2032)
  • Figure 15: In Situ Hybridization Market in the United Kingdom (2022-2032)
  • Figure 16: In Situ Hybridization Market in Italy (2022-2032)
  • Figure 17: In Situ Hybridization Market in Spain (2022-2032)
  • Figure 18: In Situ Hybridization Market in Rest of Europe (2022-2032)
  • Figure 19: In Situ Hybridization Market in Asia-Pacific (2022-2032)
  • Figure 20: In Situ Hybridization Market in China (2022-2032)
  • Figure 21: In Situ Hybridization Market in Japan (2022-2032)
  • Figure 22: In Situ Hybridization Market in India (2022-2032)
  • Figure 23: In Situ Hybridization Market in Australia (2022-2032)
  • Figure 24: In Situ Hybridization Market in South Korea (2022-2032)
  • Figure 25: In Situ Hybridization Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: In Situ Hybridization Market in Rest of the World (2022-2032)
  • Figure 27: In Situ Hybridization Market in the Middle East (2022-2032)
  • Figure 28: In Situ Hybridization Market in Africa (2022-2032)
  • Figure 29: In Situ Hybridization Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis
目次
Product Code: DISR0209

In Situ Hybridization Market by Product Type (Instruments, Reagents & Kits, and Software), Technology (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), and Others), Application (Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of cancer and genetic diseases and increasing incidences of neurological disorders and infectious disease

The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032. The demand for in situ hybridization is witnessing a notable surge, driven predominantly by the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.

In Situ Hybridization Market Dynamics:

ISH is used to diagnose congenital diseases such as Down's syndrome and Edward's Syndrome. It enables researchers to analyze how certain genes are expressed in tissues or organs, shedding light on their involvement in developmental processes, diseases, and physiological functions. Therefore, the rising number of people affected by genetic or some kind of rare disease is expected to contribute to the growth of the market. For instance, a report by the World Economic Forum in February 2023, stated that approximately 475 million individuals were suffering from rare conditions in 2019 which comprised 10% of the global population. Within the upcoming five years, it was anticipated that around 15.2 million people were expected to undergo clinical genomic testing specifically aimed at identifying rare conditions.

According to an article shared by Johnson & Johnson in February 2023, the estimate suggests that over 300 million individuals were affected with rare diseases as of 2023 globally. Fluorescence in situ hybridization (FISH) is a genetic testing technique used by pathologists to aid in diagnosing diseases attributed to chromosomal abnormalities. Therefore, the growing genetic and rare diseases contribute to the extensive use of in situ hybridization which is expected to drive the market growth.

According to data cited by the World Health Organization in 2022, around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020 around the world.

As per data published by Global Cancer Observatory in 2021, around 544,352 cases of non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020 worldwide. As per the same source, around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020 across the globe. In situ hybridization serves as a valuable tool in examining changes in gene expression or chromosomal irregularities linked to cancer, aiding in the discovery of potential diagnostic indicators and targets for therapeutic intervention, thereby driving market growth.

The rising cases of infectious diseases such as HIV, hepatitis, and others is another key driver for the in situ hybridization (ISH) market. In situ hybridization (ISH) amalgamates laboratory medicine with molecular genetics technology to detect infectious pathogens. Fluorescence in situ hybridization (FISH) specifically aids in identifying and pinpointing nucleotide sequences within diverse samples, all while maintaining the integrity of cellular structures. According to the World Health Organization (WHO) 2022, it was estimated that around 354 million people were living with Hepatitis B or C infections in 2022 globally.

Government support and funding are directed towards maximizing the value derived from the Rare Diseases Partnership, with the overarching goal of fostering increased levels of research and innovation in the field of rare diseases. For instance, in September 2023, UK Research and Innovation, the investment, totaling nearly USD 798.5 million (GBP 627 million), encompasses various initiatives aimed at advancing rare disease research. Notably, USD 126.9 million (GBP 99.7 million) had been allocated to MRC fellowships and NIHR career development awards between 2016 and 2021, illustrating the comprehensive support network surrounding rare disease research efforts.

However, the in situ hybridization market may face growth constraints due to various factors, including the inefficiency of detecting DNA level rearrangements and chromosome pairs and concerns regarding potential exposure to radioactivity.

In Situ Hybridization Market Segment Analysis:

In Situ Hybridization Market by Product Type (Instruments, Reagents & Kits, and Software), Technology (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), and Others), Application (Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology segment of the in situ hybridization market, the fluorescence in situ hybridization (FISH) category is estimated to account for a significant revenue share in the in situ hybridization market in 2024. This is attributed to the growing use of FISH in cancer diagnosis and research. In oncology, FISH is utilized to identify genetic changes linked with cancer, including gene amplifications, deletions, and rearrangements of chromosomes. Fluorescence in situ hybridization (FISH) is mainly used in the diagnosis, categorization, prognosis, and anticipation of treatment outcomes in cancer patients.

The application of FISH spans a broad spectrum of scientific disciplines, including genetic counseling, subcellular studies, detection and localization of chromosome mutations, species identification, biomedical research, clinical diagnosis, toxicology, chromosomal biology, and comparative genomics.

Key players in the market are developing innovative kits and reagents for fluorescence in situ hybridization (FISH) procedures. For instance, in December 2021, BioGenex, a US-based molecular pathology company launched NanoVIP. NanoVIP is a compact, fully automated bench-top system equipped with visualization kits designed for fluorescence in situ hybridization (FISH) and in-situ hybridization (ISH). Its 10-slide design ensures reliability through automation, featuring eXACT(TM) temperature control modules for individual slide positions, precise management of reaction times, and liquid level sensors for accurate liquid handling. This meticulous control ensures the delivery of clean, intense, reliable, and reproducible stains, minimizing the need for repeat procedures.

Further, in cellular biology and neuroscience, scientists utilize techniques such as fluorescence in situ hybridization (FISH) to investigate the expression, localization, and dynamics of genes within cells and tissues. This method allows for the visualization of specific genes or RNA molecules in various cell types including neuronal cells, glial cells, and others. By studying gene expression patterns and their spatial distribution, researchers gain valuable insights into brain function, development, and the underlying mechanisms of neurological disorders. Additionally, FISH can aid in the diagnosis of genetic disorders by enabling the visualization of specific chromosomal regions or genes associated with these conditions. Therefore, the wide applications of the fluorescence in situ hybridization (FISH) category is expected to contribute to the growth of the segment, thereby driving the growth of the in situ hybridization market during the forecast period.

North America is expected to dominate the Overall In-Situ Hybridization Market:

North America is estimated to dominate the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the region further propels the expansion of the North America in situ hybridization market.

Fluorescence in situ hybridization (FISH) is a diagnostic test that maps the genetic material within human cells, pinpointing specific genes or gene segments. Due to its capability to detect genetic abnormalities linked to cancer, FISH serves as a valuable tool in diagnosing certain types of the disease. For instance, according to the National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States.

According to the Centers for Disease Control and Prevention (CDC) in May 2024, approximately 5,700 babies were born with Down syndrome each year in the United States. This equates to a prevalence of about 1 in every 640 babies. In situ hybridization is used to identify an extra chromosome or an extra piece of a chromosome for diagnosis of Down syndrome. Therefore, the growing prevalence of rare and genetic diseases is expected to drive the market growth in the region.

In Situ Hybridization Market Key Players:

Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.

Recent Developmental Activities in the In-Situ Hybridization Market:

  • In January 2024, Biocare Medical, LLC, a US-based tissue diagnostic company announced its collaboration with Molecular Instruments to develop automated bioimaging. This partnership combines Biocare Medical's proficiency in automated bioimaging systems with MI's array of advanced HCR(TM) Products, establishing a new benchmark in automated in situ hybridization (ISH) and immunohistochemistry (IHC).
  • In May 2023, Bio-Techne, a US-based life sciences company launched Advanced Cell Diagnostics (ACD)-branded RNAscope(TM) in situ hybridization (ISH). RNAscope HiPlex12 Flex Kit allows for the visualization of highly multiplexed RNA biomarkers utilizing the Hyperion XTi or previous versions of the Hyperion Imaging System. This cutting-edge system facilitates the simultaneous detection and precise quantification of over 40 biomarkers from any tissue sample in a single imaging step, employing Imaging Mass Cytometry.
  • In November 2022, Biocare Medical, LLC completed the acquisition of Empire Genomics, a molecular biomarkers company pioneering in cancer research and diagnostics. This acquisition serves to complement our extensive portfolio of IHC antibodies, comprehensive molecular menu, and sophisticated automation platform.
  • In January 2022, Bio-Techne announced its partnership with Akoya Biosciences, Inc. to develop a single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples. Through this agreement, both companies worked to develop an automated spatial multiomics workflow capable of conducting rapid, in situ analysis of multiple analytes at single-cell resolution across entire slides.

Key Takeaways from the In Situ Hybridization Market Report Study

  • Market size analysis for current In Situ Hybridization Market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global In Situ Hybridization market.
  • Various opportunities available for the other competitors in the In Situ Hybridization Market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current In Situ Hybridization market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for In Situ Hybridization market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS IN SITU HYBRIDIZATION MARKET REPORT STUDY

  • In Situ Hybridization product providers
  • Research organizations and consulting companies
  • In Situ Hybridization related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in In Situ Hybridization
  • Various end-users who want to know more about the In Situ Hybridization Market and the latest technological developments in the In Situ Hybridization Market.

FREQUENTLY ASKED QUESTIONS FOR THE IN SITU HYBRIDIZATION MARKET:

1. What is In Situ Hybridization?

  • In situ hybridization (ISH) is a method in molecular biology utilized to identify and pinpoint specific nucleic acid sequences within fixed tissues, cells, or organisms. It involves pairing a labelled nucleic acid probe, complementary to the target sequence, with the sample. This probe, often tagged with a fluorescent dye, radioactive label, or another identifiable marker, binds to its complementary sequence in the sample. Following hybridization, the location of the probe within the sample is observed using microscopy or autoradiography, offering insights into the spatial arrangement of RNA or DNA molecules and facilitating the examination of gene expression patterns, chromosomal structure, and cellular interactions.

2. What is the market for In Situ Hybridization?

  • The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032.

3. What are the drivers for the In Situ Hybridization market?

  • The in situ hybridization market is slated to witness prosperity owing to factors such as the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.

4. Who are the key players operating in the In Situ Hybridization market?)

  • Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.

5. Which region has the highest share in the In Situ Hybridization market?

  • North America is estimated to dominate in the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the area further propels the expansion of the North America in situ hybridization market.

Table of Contents

1. In Situ Hybridization Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. In Situ Hybridization Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. In Situ Hybridization Market Key Factors Analysis

  • 5.1. In Situ Hybridization Market Drivers
    • 5.1.1. The escalating prevalence of cancer and genetic diseases.
    • 5.1.2. The upward trend in neurological disorders and infectious diseases
    • 5.1.3. The intensifying R&D activities and funding
  • 5.2. In Situ Hybridization Market Restraints and Challenges
    • 5.2.1. High cost associated with in situ hybridization assays
    • 5.2.2. Concerns regarding potential exposure to radioactivity
  • 5.3. In Situ Hybridization Market Opportunity
    • 5.3.1. Focus towards automation in in situ hybridization (ISH)
    • 5.3.2. Integration of artificial intelligence and deep learning in diagnostics

6. In Situ Hybridization Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. In Situ Hybridization Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagents and Kits
    • 7.1.3. Software
  • 7.2. By Technology
    • 7.2.1. Fluorescence In Situ Hybridization (FISH)
    • 7.2.2. Chromogenic In Situ Hybridization (CISH)
    • 7.2.3. Others
  • 7.3. By Application
    • 7.3.1. Cancer Diagnosis
    • 7.3.2. Genetic Diseases
    • 7.3.3. Infectious Diseases
    • 7.3.4. Others
  • 7.4. By End-User
    • 7.4.1. Hospitals and Clinics
    • 7.4.2. Diagnostic Centers
    • 7.4.3. Pharmaceutical And Biotechnology Companies
    • 7.4.4. Academic and Government Institutes
    • 7.4.5. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico In Situ Hybridization Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe In Situ Hybridization Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.3. India In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific In Situ Hybridization Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa In Situ Hybridization Market Size in USD million (2022-2032)
      • 7.5.4.3. South America In Situ Hybridization Market Size In USD Million (2022-2032)

8. In Situ Hybridization Market Company and Product Profiles

  • 8.1. Abbott Laboratories
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Agilent Technologies, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Thermo Fisher Scientific Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. F. Hoffmann-La Roche Ltd
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Merck & Co., Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. PerkinElmer Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Sysmex Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Biocare Medical, LLC
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Genemed Biotechnologies, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. NeoGenomics Laboratories
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Advanced Cell Diagnostics, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. BioView
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Bio-Rad Laboratories, Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Bio-Techne
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. QIAGEN
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. BioGenex
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. ZYTOVISION GmbH
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Promega Corporation
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Illumina, Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Danaher Corporation
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us